Cencora (NYSE:COR) Announces Quarterly Earnings Results

Key Points

• Cencora reported quarterly EPS of $4.66, beating the $4.58 consensus, while revenue of $88.35 billion topped estimates and rose 5.5% year over year.
• Fiscal 2027 adjusted EPS guidance is $19.40–$19.75, implying 8%–10% growth. However, reported operating income growth is projected at 4%–6%, and adjusted free cash flow is expected to fall to about $3.5 billion.
• Cencora plans to consolidate specialty capabilities into a new segment, targeting mid-teens long-term operating income growth and approximately $100 billion in specialty distribution revenue in fiscal 2027; it also announced a 10% quarterly dividend increase.

Cencora (NYSE:COR - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported $4.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.58 by $0.08, FiscalAI reports. The firm had revenue of $88.35 billion for the quarter, compared to analyst estimates of $87.95 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The business's revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.84 EPS.

Here are the key takeaways from Cencora's conference call:

• Cencora reported fiscal 2026 adjusted operating income growth of 14% and adjusted diluted EPS of $17.97, up 12%. Adjusted free cash flow was $3.8 billion, and the company announced a 10% increase to its quarterly dividend.
• The company is consolidating specialty capabilities into a new segment, targeting long-term operating income growth in the mid-teens; its fiscal 2027 segment outlook is 18%–21%, including the OneOncology acquisition contribution. Cencora expects specialty distribution revenue to reach approximately $100 billion in fiscal 2027.
• Fiscal 2027 adjusted EPS guidance is $19.40–$19.75, representing 8%–10% growth, or 10%–12% excluding the assumed MWI-Covetrus merger impact. Management projects operating income growth of 8.5%–11% excluding businesses in Other, ahead of its long-term targets.
• Reported fiscal 2027 operating income growth guidance is 4%–6%, with businesses in Other expected to reduce growth by about five percentage points; the Pharmaceutical Distribution and Services segment is forecast to grow operating income just 2%–4%, partly due to a customer volume shift and foreign exchange. Adjusted free cash flow is expected to decline to approximately $3.5 billion from $3.8 billion.

Cencora Price Performance

Shares of NYSE:COR traded up $11.88 during midday trading on Wednesday, reaching $352.38. The company's stock had a trading volume of 1,746,557 shares, compared to its average volume of 1,462,372. The business's fifty day simple moving average is $324.08 and its 200-day simple moving average is $317.45. The company has a debt-to-equity ratio of 3.53, a current ratio of 0.93 and a quick ratio of 0.58. Cencora has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The company has a market capitalization of $67.24 billion, a P/E ratio of 26.23, a P/E/G ratio of 1.73 and a beta of 0.58.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on COR. Morgan Stanley increased their price target on shares of Cencora from $346.00 to $377.00 and gave the stock an "overweight" rating in a research report on Friday, October 30th. Evercore reaffirmed an "outperform" rating and set a $350.00 price objective (up from $330.00) on shares of Cencora in a report on Thursday, August 6th. Bank of America upped their price objective on Cencora from $285.00 to $310.00 in a research note on Tuesday, July 21st. Weiss Ratings raised Cencora from a "buy (b-)" rating to a "buy (b)" rating in a report on Tuesday, October 6th. Finally, Wall Street Zen upgraded Cencora from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th. Fourteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, Cencora presently has an average rating of "Moderate Buy" and a consensus price target of $368.38.

Insider Transactions at Cencora

In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of the stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the sale, the executive vice president owned 19,455 shares of the company's stock, valued at $6,305,754.60. This represents a 36.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.38% of the stock is currently owned by company insiders.

Cencora News Summary

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora reported adjusted Q4 EPS of $4.66, topping analyst estimates of about $4.58, while revenue of $88.4 billion also exceeded expectations. Revenue rose 5.5% year over year, and EPS increased from $3.84 a year earlier. The company also recorded its fifth consecutive earnings beat, according to the report. Article: Cencora Surpasses Q4 Earnings and Revenue Estimates
• Positive Sentiment: Cencora raised its dividend, adding a shareholder-return positive alongside the earnings beat. The dividend increase amount was not provided in the article summary. Article: Cencora Q4 2026 Earnings: Fifth Straight Beat, Dividend Raised
• Neutral Sentiment: The company is realigning its organizational and reporting structure to strengthen execution and improve visibility. The strategic change may support focus over time, but no specific near-term financial impact was detailed. Article: Cencora Announces New Organizational and Reporting Structure

Cencora Company Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.